Companies › USWM CT
4 active drug programs in 6 registered trials: 3 Phase 1, 3 Phase 2; Oncology; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| letetresgene autoleucel (lete-cel, GSK3377794) genetically engineered T cells targeting NY-ESO-1 (CTAG1B) and LAGE-1a | CTAG1B, LAGE1 | Phase 2 | Neoplasms | Jul 2028 |
| ADP-A2M4CD8 Autologous genetically modified T-cell therapy targeting MAGE-A4 in HLA-A2+ patients | – | Phase 2 | Ovarian Cancer; Endometrial Cancer | Apr 2037 |
| Afamitresgene Autoleucel Melanoma-associated antigen 4 binding agent | MAGEA4 | Phase 2 | Synovial Sarcoma | Apr 2038 |
| Autologous genetically modified MAGE-A4ᶜ¹º³²T cells T cell receptor (TCR) engineered T cells targeting MAGE-A4 | MAGE-A4 | Phase 1 | Urinary Bladder Cancer | Sep 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05601752 | ADP-A2M4CD8 | Phase 2 | Ovarian Cancer | Oncology | Sep 2025 |
| NCT03967223 | letetresgene autoleucel (lete-cel, GSK3377794) | Phase 2 | Neoplasms | Oncology | Jul 2028 |
| NCT03132922 | Autologous genetically modified MAGE-A4ᶜ¹º³²T cells | Phase 1 | Urinary Bladder Cancer | Oncology | Sep 2032 |
| NCT04044859 | ADP-A2M4CD8 | Phase 1 | Endometrial Cancer | Oncology | Apr 2037 |
| NCT04044768 | Afamitresgene Autoleucel | Phase 2 | Synovial Sarcoma | Oncology | Apr 2038 |
| NCT05642455 | Afamitresgene Autoleucel | Phase 1 | Synovial Sarcoma | Oncology | Jul 2038 |
Immatics Biotechnologies Zelluna Immunotherapy PDC*line Pharma SAS CDR-Life
CNBG-Virogin Biotech (Shanghai) Stella Pharma Dendreon Hrain Biotechnology Marzieh Ebrahimi
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.